Shamburg News · 8-K filed Oct 20, 2026, 8:53 AM EDT
Freenome Launches SimpleScreen Lung Test, Adds Option to Pair With SimpleScreen CRC
FRNM · Freenome, Inc.
- Other event
- Other
- Materiality: low
On October 20, 2026, Freenome, Inc. announced the launch of SimpleScreen Lung, a laboratory-developed blood-based lung cancer test, and an offering that lets eligible patients be screened for both lung and colorectal cancer through a single blood draw. SimpleScreen Lung showed 85% sensitivity at 50% specificity and a 99.8% negative predictive value in an independent cohort of 172 cases and 436 controls. The company also reported that its PREEMPT CRC study, which enrolled more than 48,000 participants, showed 81% sensitivity for colorectal cancer. The information was furnished under Regulation FD and Item 8.01.
Source: SEC EDGAR, Form 8-K, Items 7.01, 8.01, 9.01, accession 0001140361-26-040186.
Written from the filing by Shamburg Markets. Figures are as reported by the company.